Sign in
Taking people in United StatesPhase 2

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Key facts

Who runs it
Frantz Viral Therapeutics, LLC
Where
Ann Arbor, Cleveland, Fort Myers, Houston, and Mayfield Heights, United StatesSee the 7 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
78 people, planned
Started
9 Sept 2020
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Artesunate vaginal insert
  • Placebo vaginal insert
Record updated
2 October 2025

Who can take part

Age
25 years to 100 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adult females age ≥ 25 years
  • Capable of informed consent
  • Any HPV genotype detectable by DNA test/HPV genotyping
  • Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)
  • Women of childbearing potential agree to use birth control through week17 of the study
  • Weight ≥ 50kg

Who cannot take part

  • Taking immunosuppressive medication
  • Evidence of concurrent cervical adenocarcinoma in situ
  • Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects
  • Active autoimmune disease
  • HIV seropositivity
  • Pregnant and nursing women
  • Immunocompromised subjects

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 25 and 100 years old?

This trial is currently available in United States.

  • University of MichiganAnn Arbor, United StatesContact: Mubeenah SyedahTaking people
  • Cleveland Clinic Fairview HospitalCleveland, United StatesContact: Donna WhiteTaking people
  • Cleveland Clinic FoundationCleveland, United StatesContact: Donna WhiteTaking people
  • Florida Gynecologic OncologyFort Myers, United StatesContact: Cami HansenTaking people
  • The Harris Health System (L.B.J Hospital)Houston, United StatesContact: Jessica GallegosTaking people
  • University of Texas, M.D. AndersonHouston, United StatesContact: Jessica GallegosTaking people
  • Hillcrest HospitalMayfield Heights, United StatesContact: Donna WhiteTaking people

About the trial

What the trial wants to find out

This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).

The 2 groups in the trial

  • Artesunate vaginal insertTreatment being tested

    Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.

  • Placebo vaginal insertsPlacebo, for comparison

    Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4.

    Treatment: Placebo vaginal insert

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
Criteria questions
Built from NCT04098744, who can take part
Record updated
2 October 2025